胃癌術后胰瘺再認識_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

唐兆慶 ,  劉鳳林

復旦大學附屬中山醫院普外科（上海 200032）;

Corresponding?author：

劉鳳林, Email: liu.fenglin@zs-hospital.sh.cn

Keywords：

DOI：

10.7507/1007-9424.202104101

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 唐兆慶, 劉鳳林. 胃癌術后胰瘺再認識. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(6): 712-716. doi: 10.7507/1007-9424.202104101 Copy

1.	Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1): 11-20.
2.	Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, 2019, 393(10184): 1948-1957.
3.	Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet, 1996, 347(9007): 995-999.
4.	Von Mikulicz-Radecki. I. Surgery of the pancreas with especial consideration of trauma and inflammatory processes. Ann Surg, 1903, 38(1): 1-29.
5.	Sano T, Sasako M, Katai H, et al. Amylase concentration of drainage fluid after total gastrectomy. Br J Surg, 1997, 84(9): 1310-1312.
6.	蘇向前, 周傳永, 楊宏. 胃癌根治術后胰瘺預防與治療. 中國實用外科雜志, 2017, 37(4): 345-348.
7.	孫益紅, 王洪山. 胃癌根治術相關胰瘺預防及處理. 中國實用外科雜志, 2015, 35(8): 838-840.
8.	Aranha GV, Aaron JM, Shoup M, et al. Current management of pancreatic fistula after pancreaticoduodenectomy. Surgery, 2006, 140(4): 561-568.
9.	Furukawa H, Hiratsuka M, Iwanaga T, et al. Extended surgery—left upper abdominal exenteration plus Appleby’s method—for type 4 gastric carcinoma. Ann Surg Oncol, 1997, 4(3): 209-214.
10.	Otsuji E, Yamaguchi T, Sawai K, et al. Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. Br J Cancer, 1999, 79(11-12): 1789-1793.
11.	Furukawa H, Hiratsuka M, Ishikawa O, et al. Total gastrectomy with dissection of lymph nodes along the splenic artery: a pancreas-preserving method. Ann Surg Oncol, 2000, 7(9): 669-673.
12.	Sano T, Sasako M, Mizusawa J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg, 2017, 265(2): 277-283.
13.	Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med, 2008, 359(5): 453-462.
14.	Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg, 2009, 250(2): 187-196.
15.	Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg, 2004, 240(2): 205-213.
16.	Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol, 2018, 3(7): 460-468.
17.	Terashima M, Iwasaki Y, Mizusawa J, et al. Randomized phase Ⅲ trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer, 2019, 22(5): 1044-1052.
18.	Ito S, Sano T, Mizusawa J, et al. A phase Ⅱ study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer, 2017, 20(2): 322-331.
19.	Katai H, Sasako M, Fukuda H, et al. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase Ⅱ trial (JCOG 0703). Gastric Cancer, 2010, 13(4): 238-244.
20.	Katai H, Mizusawa J, Katayama H, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage Ⅰ A or Ⅰ B gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol, 2020, 5(2): 142-151.
21.	Kim W, Kim HH, Han SU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage Ⅰ gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg, 2016, 263(1): 28-35.
22.	Katai H, Mizusawa J, Katayama H, et al. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage Ⅰgastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer, 2019, 22(5): 999-1008.
23.	Hyung WJ, Yang HK, Han SU, et al. A feasibility study of laparoscopic total gastrectomy for clinical stage Ⅰ gastric cancer: a prospective multi-center phase Ⅱ clinical trial, KLASS 03. Gastric Cancer, 2019, 22(1): 214-222.
24.	Liu F, Huang C, Xu Z, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰgastric cancer: The CLASS02 multicenter randomized clinical trial. JAMA Oncol, 2020, 6(10): 1590-1597.
25.	Inaki N, Etoh T, Ohyama T, et al. a multi-institutional, prospective, phase Ⅱ feasibility study of laparoscopy-assisted distal gastrectomy with d2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). World J Surg, 2015, 39(11): 2734-2741.
26.	Lee HJ, Hyung WJ, Yang HK, et al. Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with d2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT). Ann Surg, 2019, 270(6): 983-991.
27.	Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open d2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol, 2016, 34(12): 1350-1357.
28.	Li Z, Shan F, Ying X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial. JAMA Surg, 2019, 154(12): 1093-1101.
29.	Nakauchi M, Suda K, Kadoya S, et al. Technical aspects and short- and long-term outcomes of totally laparoscopic total gastrectomy for advanced gastric cancer: a single-institution retrospective study. Surg Endosc, 2016, 30(10): 4632-4639.
30.	Nakauchi M, Suda K, Susumu S, et al. Comparison of the long-term outcomes of robotic radical gastrectomy for gastric cancer and conventional laparoscopic approach: a single institutional retrospective cohort study. Surg Endosc, 2016, 30(12): 5444-5452.
31.	Okabe H, Obama K, Tsunoda S, et al. Feasibility of robotic radical gastrectomy using a monopolar device for gastric cancer. Surg Today, 2019, 49(10): 820-827.
32.	Uyama I, Suda K, Nakauchi M, et al. Clinical advantages of robotic gastrectomy for clinical stage Ⅰ / Ⅱ gastric cancer: a multi-institutional prospective single-arm study. Gastric Cancer, 2019, 22(2): 377-385.
33.	Yang K, Cho M, Roh CK, et al. Robotic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer. Surg Endosc, 2019, 33(7): 2357-2363.
34.	Lu J, Zheng CH, Xu BB, et al. Assessment of Robotic versus laparoscopic distal gastrectomy for gastric cancer: a randomized controlled trial. Ann Surg, 2021, 273(5): 858-867.
35.	Kim HI, Han SU, Yang HK, et al. Multicenter prospective comparative study of Robotic versus laparoscopic gastrectomy for gastric adenocarcinoma. Ann Surg, 2016, 263(1): 103-109.
36.	Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery, 2005, 138(1): 8-13.
37.	Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery, 2017, 161(3): 584-591.
38.	Kung CH, Lindblad M, Nilsson M, et al. Postoperative pancreatic fistula formation according to ISGPF criteria after D2 gastrectomy in Western patients. Gastric Cancer, 2014, 17(3): 571-577.
39.	Miki Y, Tokunaga M, Bando E, et al. Evaluation of postoperative pancreatic fistula after total gastrectomy with D2 lymphadenectomy by ISGPF classification. J Gastrointest Surg, 2011, 15(11): 1969-1976.
40.	Katayama H, Kurokawa Y, Nakamura K, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today, 2016, 46(6): 668-685.
41.	Kobayashi D, Iwata N, Tanaka C, et al. Factors related to occurrence and aggravation of pancreatic fistula after radical gastrectomy for gastric cancer. J Surg Oncol, 2015, 112(4): 381-386.
42.	Kanda M, Fujiwara M, Tanaka C, et al. Predictive value of drain amylase content for peripancreatic inflammatory fluid collections after laparoscopic (assisted) distal gastrectomy. Surg Endosc, 2016, 30(10): 4353-4362.
43.	Taniguchi Y, Kurokawa Y, Mikami J, et al. Amylase concentration in drainage fluid as a predictive factor for severe postoperative pancreatic fistula in patients with gastric cancer. Surg Today, 2017, 47(11): 1378-1383.
44.	Tomimaru Y, Miyashiro I, Kishi K, et al. Is routine measurement of amylase concentration in drainage fluid necessary after total gastrectomy for gastric cancer? J Surg Oncol, 2011, 104(3): 274-277.
45.	Wang Z, Chen J, Su K, et al. Abdominal drainage versus no drainage post-gastrectomy for gastric cancer. Cochrane Database Syst Rev, 2015, 2015(5): CD008788.
46.	Messager M, Sabbagh C, Denost Q, et al. Is there still a need for prophylactic intra-abdominal drainage in elective major gastro-intestinal surgery? J Visc Surg, 2015, 152(5): 305-313.
47.	唐兆慶, 趙剛, 臧潞, 等. 胃癌根治術后胰瘺發生率及其影響因素分析的多中心前瞻性研究(附2 089例報告). 中華消化外科雜志, 2020, 19(1): 63-71.

1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1): 11-20.
2. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, 2019, 393(10184): 1948-1957.
3. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet, 1996, 347(9007): 995-999.
4. Von Mikulicz-Radecki. I. Surgery of the pancreas with especial consideration of trauma and inflammatory processes. Ann Surg, 1903, 38(1): 1-29.
5. Sano T, Sasako M, Katai H, et al. Amylase concentration of drainage fluid after total gastrectomy. Br J Surg, 1997, 84(9): 1310-1312.
6. 蘇向前, 周傳永, 楊宏. 胃癌根治術后胰瘺預防與治療. 中國實用外科雜志, 2017, 37(4): 345-348.
7. 孫益紅, 王洪山. 胃癌根治術相關胰瘺預防及處理. 中國實用外科雜志, 2015, 35(8): 838-840.
8. Aranha GV, Aaron JM, Shoup M, et al. Current management of pancreatic fistula after pancreaticoduodenectomy. Surgery, 2006, 140(4): 561-568.
9. Furukawa H, Hiratsuka M, Iwanaga T, et al. Extended surgery—left upper abdominal exenteration plus Appleby’s method—for type 4 gastric carcinoma. Ann Surg Oncol, 1997, 4(3): 209-214.
10. Otsuji E, Yamaguchi T, Sawai K, et al. Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. Br J Cancer, 1999, 79(11-12): 1789-1793.
11. Furukawa H, Hiratsuka M, Ishikawa O, et al. Total gastrectomy with dissection of lymph nodes along the splenic artery: a pancreas-preserving method. Ann Surg Oncol, 2000, 7(9): 669-673.
12. Sano T, Sasako M, Mizusawa J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg, 2017, 265(2): 277-283.
13. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med, 2008, 359(5): 453-462.
14. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg, 2009, 250(2): 187-196.
15. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg, 2004, 240(2): 205-213.
16. Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol, 2018, 3(7): 460-468.
17. Terashima M, Iwasaki Y, Mizusawa J, et al. Randomized phase Ⅲ trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer, 2019, 22(5): 1044-1052.
18. Ito S, Sano T, Mizusawa J, et al. A phase Ⅱ study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer, 2017, 20(2): 322-331.
19. Katai H, Sasako M, Fukuda H, et al. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase Ⅱ trial (JCOG 0703). Gastric Cancer, 2010, 13(4): 238-244.
20. Katai H, Mizusawa J, Katayama H, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage Ⅰ A or Ⅰ B gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol, 2020, 5(2): 142-151.
21. Kim W, Kim HH, Han SU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage Ⅰ gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg, 2016, 263(1): 28-35.
22. Katai H, Mizusawa J, Katayama H, et al. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage Ⅰgastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer, 2019, 22(5): 999-1008.
23. Hyung WJ, Yang HK, Han SU, et al. A feasibility study of laparoscopic total gastrectomy for clinical stage Ⅰ gastric cancer: a prospective multi-center phase Ⅱ clinical trial, KLASS 03. Gastric Cancer, 2019, 22(1): 214-222.
24. Liu F, Huang C, Xu Z, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰgastric cancer: The CLASS02 multicenter randomized clinical trial. JAMA Oncol, 2020, 6(10): 1590-1597.
25. Inaki N, Etoh T, Ohyama T, et al. a multi-institutional, prospective, phase Ⅱ feasibility study of laparoscopy-assisted distal gastrectomy with d2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). World J Surg, 2015, 39(11): 2734-2741.
26. Lee HJ, Hyung WJ, Yang HK, et al. Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with d2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT). Ann Surg, 2019, 270(6): 983-991.
27. Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open d2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol, 2016, 34(12): 1350-1357.
28. Li Z, Shan F, Ying X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial. JAMA Surg, 2019, 154(12): 1093-1101.
29. Nakauchi M, Suda K, Kadoya S, et al. Technical aspects and short- and long-term outcomes of totally laparoscopic total gastrectomy for advanced gastric cancer: a single-institution retrospective study. Surg Endosc, 2016, 30(10): 4632-4639.
30. Nakauchi M, Suda K, Susumu S, et al. Comparison of the long-term outcomes of robotic radical gastrectomy for gastric cancer and conventional laparoscopic approach: a single institutional retrospective cohort study. Surg Endosc, 2016, 30(12): 5444-5452.
31. Okabe H, Obama K, Tsunoda S, et al. Feasibility of robotic radical gastrectomy using a monopolar device for gastric cancer. Surg Today, 2019, 49(10): 820-827.
32. Uyama I, Suda K, Nakauchi M, et al. Clinical advantages of robotic gastrectomy for clinical stage Ⅰ / Ⅱ gastric cancer: a multi-institutional prospective single-arm study. Gastric Cancer, 2019, 22(2): 377-385.
33. Yang K, Cho M, Roh CK, et al. Robotic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer. Surg Endosc, 2019, 33(7): 2357-2363.
34. Lu J, Zheng CH, Xu BB, et al. Assessment of Robotic versus laparoscopic distal gastrectomy for gastric cancer: a randomized controlled trial. Ann Surg, 2021, 273(5): 858-867.
35. Kim HI, Han SU, Yang HK, et al. Multicenter prospective comparative study of Robotic versus laparoscopic gastrectomy for gastric adenocarcinoma. Ann Surg, 2016, 263(1): 103-109.
36. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery, 2005, 138(1): 8-13.
37. Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery, 2017, 161(3): 584-591.
38. Kung CH, Lindblad M, Nilsson M, et al. Postoperative pancreatic fistula formation according to ISGPF criteria after D2 gastrectomy in Western patients. Gastric Cancer, 2014, 17(3): 571-577.
39. Miki Y, Tokunaga M, Bando E, et al. Evaluation of postoperative pancreatic fistula after total gastrectomy with D2 lymphadenectomy by ISGPF classification. J Gastrointest Surg, 2011, 15(11): 1969-1976.
40. Katayama H, Kurokawa Y, Nakamura K, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today, 2016, 46(6): 668-685.
41. Kobayashi D, Iwata N, Tanaka C, et al. Factors related to occurrence and aggravation of pancreatic fistula after radical gastrectomy for gastric cancer. J Surg Oncol, 2015, 112(4): 381-386.
42. Kanda M, Fujiwara M, Tanaka C, et al. Predictive value of drain amylase content for peripancreatic inflammatory fluid collections after laparoscopic (assisted) distal gastrectomy. Surg Endosc, 2016, 30(10): 4353-4362.
43. Taniguchi Y, Kurokawa Y, Mikami J, et al. Amylase concentration in drainage fluid as a predictive factor for severe postoperative pancreatic fistula in patients with gastric cancer. Surg Today, 2017, 47(11): 1378-1383.
44. Tomimaru Y, Miyashiro I, Kishi K, et al. Is routine measurement of amylase concentration in drainage fluid necessary after total gastrectomy for gastric cancer? J Surg Oncol, 2011, 104(3): 274-277.
45. Wang Z, Chen J, Su K, et al. Abdominal drainage versus no drainage post-gastrectomy for gastric cancer. Cochrane Database Syst Rev, 2015, 2015(5): CD008788.
46. Messager M, Sabbagh C, Denost Q, et al. Is there still a need for prophylactic intra-abdominal drainage in elective major gastro-intestinal surgery? J Visc Surg, 2015, 152(5): 305-313.
47. 唐兆慶, 趙剛, 臧潞, 等. 胃癌根治術后胰瘺發生率及其影響因素分析的多中心前瞻性研究(附2 089例報告). 中華消化外科雜志, 2020, 19(1): 63-71.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

胃癌術后胰瘺再認識

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content